MAYO CLINIC
Mayo Medical Laboratories

# Laboratory Service Report 1-800-533-1710

| Patient Name | Patient ID | Age | Gender | Order # |
|---|---|---|---|---|
| REPORTVALIDATION,AUTOMATION D... | RVDMOHB025 | 40 | F | RVDMOHB025 |
| **Ordering Phys** | | **DOB** 01/01/1971 | | |

| Client Order # | Account Information | Report Notes |
|---|---|---|
| RVDMOHB025 | C7028846-DLMP ROCHESTER<br>3050 SUPERIOR DRIVE<br>ROCHESTER,MN 55901 | |
| **Collected** 09/01/2011 08:48 | | |
| **Printed** 09/02/2011 07:01 | | |

| Test | Flag | Results | Unit | Reference Value | Perform Site* |
|---|---|---|---|---|---|
| **BCR/ABL, p210, Quant, Monitor** | | | REPORTED 09/01/2011 11:37 | | |
| Specimen Type | | Peripheral blood | | | MCR |
| Final Diagnosis: | | | | | MCR |

REVISED RESULTS
Peripheral blood, BCR/ABL mRNA level analysis (p210 fusion form):

Positive. BCR/ABL p210 mRNA transcripts were detected and estimated to represent 70% of total abl (%bcr/abl(p210):abl).

Previous specimens from this patient have been tested in this laboratory using this method and a summary of results will be faxed provided our laboratory has a current, secure fax number on file. If a faxed report is not received, please call the Mayo Clinic Molecular Hematopathology Laboratory (1-507-266-0489) to provide a fax number.

Signing Pathologist: Carey Lueck
Method summary - BCR/ABL, p210 fusion: p210 mRNA transcript level was evaluated using quantitative, reverse transcription PCR. The assay detects the two most common fusion forms in chronic myelogenous leukemia: e13/a2 and e14/a2, which code for p210 proteins. It is intended for monitoring patients with neoplasms known to carry the p210 fusion form. The assay does not detect other fusions, including those for the p190 protein commonly present in acute lymphoblastic leukemia. This assay should not be used in the diagnostic setting, as it does not detect all bcr/abl fusion forms. If this has been ordered in a diagnostic setting and the result is negative, test #89006 (BCR/ABL mRNA Detection, RT-PCR, Qualitative, Diagnostic) should be ordered to evaluate for all possible fusion forms. Please contact the lab at 1-507-266-0489 with questions or if additional testing is required. See the Mayo Medical Laboratories Interpretive Handbook for method details.

Typical clinical samples have detection limits ranging from 0.01% to 0.0001% bcr/abl:abl. Most CML patients at diagnosis have a bcr/abl:abl result in the range of 20% to 100%.

The reproducibility of this assay is such that results

| **Patient Name** | **Patient ID** | **Age** | **Gender** | **Order #** |
|---|---|---|---|---|
| REPORTVALIDATION,AUTOMATION D... | RVDMOHB025 | 40 | F | RVDMOHB025 |
| **Ordering Phys** | | **DOB** 01/01/1971 | | |

| **Client Order #** | **Account Information** | **Report Notes** |
|---|---|---|
| RVDMOHB025 | | |
| **Collected** 09/01/2011 08:48 | C7028846-DLMP ROCHESTER<br>3050 SUPERIOR DRIVE<br>ROCHESTER,MN 55901 | |
| **Printed** 09/02/2011 07:01 | | |

| Test | Flag | Results | Unit | Reference Value | Perform Site* |
|---|---|---|---|---|---|

within 0.5 log should be considered equivalent. Trends in the level of BCR/ABL mRNA should be followed and clinically significant changes verified with a subsequent specimen.
Laboratory developed test.

* Performing Site:

| | | |
|---|---|---|
| MCR | Mayo Clinic Dpt of Lab Med & Pathology<br>200 First St SW Rochester, MN 55905 | Lab Director: |